Aimed at stoking growth in its diagnostic tests, Enzo Biochem (ENZ) announces the following key initiatives:
New York State Health Department approval for oral and rectal sexually transmitted infection (STI) (recently OK’d for its gonorrhea and chlamydia tests for oral and rectal specimens).
Create a direct-to-consumer business for STI tests.
Build a new lab-to-labs business model that leverages the scale of its central lab with smaller labs.
Expand offerings to clinical research organizations, academic research institutions and the pharma industry.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.